Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA RYAN RICHTER

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1982879128
CMS profile
45118
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$164,093.62

110 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–110 of 110 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA RYAN RICHTER

NPI 1982879128 · CMS profile ID 45118

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–110 of 110 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982879128?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA RYAN RICHTER, NPI 1982879128, CMS profile ID 45118. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–110 of 110 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982879128?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOSHUA RYAN RICHTER, NPI 1982879128, CMS profile ID 45118. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–110 of 110 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982879128?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOSHUA RYAN RICHTER, NPI 1982879128, CMS profile ID 45118, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–110 of 110 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1982879128?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

110 matching records · $164,093.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 110 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–110 of 110.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $372.5002/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055565403 CMS
PFIZER INC. $6,300.0002/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050309969 CMS
Janssen Biotech, Inc. $1,010.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988472309 CMS
Janssen Global Services, LLC $3,850.0001/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988238051 CMS
Janssen Global Services, LLC $228.1401/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988238065 CMS
Janssen Global Services, LLC $216.1201/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988238077 CMS
Celgene Corporation $889.5001/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015418601 CMS
E.R. Squibb & Sons, L.L.C. $889.5001/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015418101 CMS
Janssen Global Services, LLC $350.0001/20/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988238039 CMS
F. Hoffmann-La Roche AG $760.0001/01/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040417205 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $93,646.76 76
PY2020 $98,240.00 59
PY2021 $177,170.00 96
PY2022 $150,933.81 86
PY2023 $164,093.62 110
PY2024 $200,095.39 81
PY2025 $86,330.57 43

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $14,747.87 37
PY2025 Principal investigator $3,691,471.50 83
PY2024 Recipient $9,987.67 20
PY2024 Principal investigator $5,270,927.23 85
PY2023 Recipient $156,959.97 23
PY2023 Principal investigator $7,308,559.63 70
PY2022 Recipient $25,455.37 16
PY2022 Principal investigator $1,368,475.26 27
PY2021 Recipient $24,745.77 6
PY2021 Principal investigator $1,185,912.34 24
PY2020 Recipient $64,501.00 8
PY2020 Principal investigator $33,510.00 2
PY2019 Recipient $850.36 2
PY2019 Principal investigator $74,284.80 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,395.48 12/25/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175315545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 12/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184279954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 12/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184279956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 12/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184279958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 12/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184279960
Principal investigator 1 Genentech, Inc. $10,627.00 12/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,836.60 12/11/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184270191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $900.00 12/11/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184270193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,956.30 12/10/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184269801
Recipient Regeneron Pharmaceuticals, Inc. $192.00 12/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,303.86 11/20/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184263269
Principal investigator 1 Janssen Research & Development, LLC $11,093.22 11/06/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175315395
Recipient Regeneron Pharmaceuticals, Inc. $1,826.20 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121793
Recipient Regeneron Pharmaceuticals, Inc. $92.16 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121795
Recipient Regeneron Pharmaceuticals, Inc. $192.00 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121797
Recipient Regeneron Pharmaceuticals, Inc. $115.20 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121799
Recipient Regeneron Pharmaceuticals, Inc. $104.73 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,756.25 11/06/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184257717
Principal investigator 1 Genentech, Inc. $7,250.00 10/20/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89,752.40 10/14/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184250059
Principal investigator 1 SANOFI US SERVICES INC. $78,291.90 10/13/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090790
Principal investigator 1 SANOFI US SERVICES INC. $130,487.70 10/13/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090796
Recipient Regeneron Pharmaceuticals, Inc. $366.06 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121789
Recipient Regeneron Pharmaceuticals, Inc. $256.64 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121791
Principal investigator 1 Janssen Research & Development, LLC $3,697.74 09/29/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175315187
Principal investigator 1 Janssen Scientific Affairs, LLC $3,000.00 09/25/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Longitudinal Multi-Center Chart Review Data Repository For Multiple Myeloma No dispute reported 06/30/2026 1174942582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $182.24 09/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184241962
Recipient Regeneron Pharmaceuticals, Inc. $445.00 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121777
Recipient Regeneron Pharmaceuticals, Inc. $111.40 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121779
Recipient Regeneron Pharmaceuticals, Inc. $263.89 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121781
Recipient Regeneron Pharmaceuticals, Inc. $388.71 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121783
Recipient Regeneron Pharmaceuticals, Inc. $1,361.28 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121785
Recipient Regeneron Pharmaceuticals, Inc. $152.24 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121787
Principal investigator 1 Genentech, Inc. $22,500.00 09/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211613761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,562.60 09/11/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184235907
Principal investigator 1 SANOFI US SERVICES INC. $130,487.70 08/28/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090769
Principal investigator 1 SANOFI US SERVICES INC. $78,291.90 08/28/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65,000.00 08/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184230695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $346.01 08/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184230699
Principal investigator 1 SANOFI US SERVICES INC. $15,658.38 08/25/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090763
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 08/22/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314819
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/22/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85,771.66 08/19/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184228693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $60.75 08/13/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184226893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40,500.00 08/13/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184226901
Principal investigator 1 Janssen Research & Development, LLC $7,395.48 08/08/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175315666
Principal investigator 1 Genentech, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211613765
Principal investigator 1 Genentech, Inc. $84,000.00 08/06/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Ph I of FcRH5 CD3 in multiple myeloma No dispute reported 06/30/2026 1211613769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,925.45 08/06/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184223626
Principal investigator 1 Genentech, Inc. $614.00 08/05/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613829
Principal investigator 1 Genentech, Inc. $5,700.00 08/05/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613831
Recipient Regeneron Pharmaceuticals, Inc. $74.32 07/29/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121773
Recipient Regeneron Pharmaceuticals, Inc. $196.82 07/29/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121775
Recipient Regeneron Pharmaceuticals, Inc. $1,900.00 07/23/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $309.81 07/22/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184217559
Principal investigator 1 SANOFI US SERVICES INC. $43,495.90 07/21/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090741
Principal investigator 1 SANOFI US SERVICES INC. $62,633.52 07/21/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090748
Principal investigator 1 SANOFI US SERVICES INC. $86,991.80 07/21/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090755
Recipient Regeneron Pharmaceuticals, Inc. $340.00 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121759
Recipient Regeneron Pharmaceuticals, Inc. $310.68 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121761
Recipient Regeneron Pharmaceuticals, Inc. $668.60 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121763
Recipient Regeneron Pharmaceuticals, Inc. $146.62 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121765
Recipient Regeneron Pharmaceuticals, Inc. $121.27 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121767
Recipient Regeneron Pharmaceuticals, Inc. $46.75 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52,254.51 07/09/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184213369
Principal investigator 1 Genentech, Inc. $1,842.00 07/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613816
Principal investigator 1 Genentech, Inc. $6,798.00 07/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613821
Principal investigator 1 Genentech, Inc. $3,000.00 07/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.31 07/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
SHORT-TERM LINVOSELTAMAB TREATMENT, ON TOP OF CHRONIC DUPILUMAB TREATMENT, FOR ADULTS WITH SEVERE IMMUNOGLOBULIN E (IGE)-MEDIATED FOOD ALLERGY No dispute reported 06/30/2026 1184212345
Principal investigator 1 Janssen Research & Development, LLC $3,697.74 06/30/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314930
Recipient Regeneron Pharmaceuticals, Inc. $227.11 06/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121757
Principal investigator 1 Janssen Research & Development, LLC $12,000.00 06/12/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314825
Recipient Regeneron Pharmaceuticals, Inc. $807.25 06/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,012.50 06/05/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184204063
Principal investigator 1 SANOFI US SERVICES INC. $126,441.60 06/04/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090680
Principal investigator 1 SANOFI US SERVICES INC. $75,864.60 06/04/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090685
Principal investigator 1 Janssen Research & Development, LLC $3,697.74 06/02/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314193
Recipient Regeneron Pharmaceuticals, Inc. $264.32 06/02/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121753
Recipient Regeneron Pharmaceuticals, Inc. $468.42 06/01/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.27 05/28/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184198795
Principal investigator 1 SANOFI US SERVICES INC. $126,441.60 05/19/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090669
Principal investigator 1 SANOFI US SERVICES INC. $58,162.86 05/19/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090674
Recipient Regeneron Pharmaceuticals, Inc. $304.53 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121747
Recipient Regeneron Pharmaceuticals, Inc. $195.26 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121749
Principal investigator 1 Janssen Research & Development, LLC $3,697.74 04/28/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314714
Recipient Regeneron Pharmaceuticals, Inc. $121.27 04/24/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,450.00 04/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184189197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103.27 04/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184189199
Principal investigator 1 Amgen Inc. $863,028.00 04/16/2025 Covered Recipient Teaching Hospital
JERSEY SHORE UNIVERSITY MED CTR
A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination with Carfilzomib, High-dose Carfilzomib and Dexamethasone, and Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1246637488
Recipient Regeneron Pharmaceuticals, Inc. $82.29 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121741
Recipient Regeneron Pharmaceuticals, Inc. $88.62 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121743
Recipient Regeneron Pharmaceuticals, Inc. $412.60 04/10/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121739
Recipient Regeneron Pharmaceuticals, Inc. $181.31 04/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121737
Principal investigator 1 SANOFI US SERVICES INC. $126,441.60 04/07/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090654
Principal investigator 1 SANOFI US SERVICES INC. $75,864.60 04/07/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226090663
Principal investigator 1 Janssen Research & Development, LLC $7,395.48 03/31/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175315053
Principal investigator 1 SANOFI US SERVICES INC. $126,441.60 03/25/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226097199
Principal investigator 1 SANOFI US SERVICES INC. $75,864.60 03/25/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226097206
Principal investigator 1 Janssen Research & Development, LLC $340,200.00 03/03/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT S INAI
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175314631
Recipient Regeneron Pharmaceuticals, Inc. $1,652.68 02/28/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,731.53 02/27/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184156188
Principal investigator 1 Genentech, Inc. $18,327.00 02/19/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613834
Principal investigator 1 Genentech, Inc. $68,710.00 02/13/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients No dispute reported 06/30/2026 1211613837
Recipient Regeneron Pharmaceuticals, Inc. $111.95 02/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121731
Recipient Regeneron Pharmaceuticals, Inc. $157.69 02/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184121733
Principal investigator 1 Epizyme, Inc. $473.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282883
Principal investigator 1 Epizyme, Inc. $2,430.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282885
Principal investigator 1 Epizyme, Inc. $434.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282887
Principal investigator 1 Epizyme, Inc. $210.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282889
Principal investigator 1 Epizyme, Inc. $2,026.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282891
Principal investigator 1 Epizyme, Inc. $810.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282893
Principal investigator 1 Epizyme, Inc. $270.00 01/31/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282895
Principal investigator 1 Epizyme, Inc. $9,000.00 01/17/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282879
Principal investigator 1 Epizyme, Inc. $5,076.00 01/17/2025 Non-covered Recipient Entity
Mount Sinai Hospital
A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1184282881
Principal investigator 1 Janssen Scientific Affairs, LLC $19,687.50 01/09/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
A Retrospective Record Review of DRd and DVRd in Newly Diagnosed Multiple Myeloma patients who are not eligible for transplant No dispute reported 06/30/2026 1174942532
Principal investigator 1 Janssen Scientific Affairs, LLC $5,000.00 01/09/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
A Retrospective Record Review of DRd and DVRd in Newly Diagnosed Multiple Myeloma patients who are not eligible for transplant No dispute reported 06/30/2026 1174942547
Principal investigator 1 Janssen Scientific Affairs, LLC $7,000.00 01/09/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
A Retrospective Record Review of DRd and DVRd in Newly Diagnosed Multiple Myeloma patients who are not eligible for transplant No dispute reported 06/30/2026 1174942568
Principal investigator 1 Janssen Scientific Affairs, LLC $44,250.00 01/09/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
A Retrospective Record Review of DRd and DVRd in Newly Diagnosed Multiple Myeloma patients who are not eligible for transplant No dispute reported 06/30/2026 1174942593
Principal investigator 1 SANOFI US SERVICES INC. $126,441.60 01/07/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226097216
Principal investigator 1 SANOFI US SERVICES INC. $75,864.60 01/07/2025 Non-covered Recipient Entity
John Theurer Cancer Center At Hackensack Umc
IST- Tolerance Combination Dose-Carfilzomide-IV No dispute reported 06/30/2026 1226097222